Clinical problems in transfusion medicine and hemostasis have rarely been the subject of clinical studies to determine the adequacy of therapy. Common problems such as the appropriate transfusion dose of platelets or fresh frozen plasma (FFP) as well as the optimal therapy for immune thrombocytopenic purpura (IIP) and thrombotic thrombocytopenic purpura (TTP) are not understood. With the creation of the Transfusion Medicine and Hemostasis (TMH) Clinical Trials Network (CTN) a structure has been created to answer these clinical problems. The MGH has served for the past 4 years as a Clinical Core Center (CCC) and has provided much of the senior leadership to the TMH CTN as well as developed half of the protocols currently active. The objectives of this proposal are: (1) To maintain the MGH CCC. We seek to continue to support the Investigators and Research Nurse/Data Coordinator who will design and carry out all study procedures for the TMHCTN clinical trials. We will also maintain the MGH resources and data collection facilities used by the Staff to conduct these studies as well as support the attendance of the Staff at TMH CTN meetings. (2) To support the TMH Fellow. Each year a TMH Fellow is appointed who oversees the clinical trials with the Staff and learns how to conduct clinical trials. (3) To support the TMH CTN trials at the MGH: (a) The SHIP Trial to determine whether FFP will reduce the incidence of hemorrhage in patients with an elevated INR undergoing invasive procedures;(b) The PLADO Trial to determine the appropriate dose of platelets to reduce the risk of bleeding in thrombocytopenic patients;(c) The HOT Trial to assess the rate of thrombosis and complications of therapy for patients with heparin-induced thrombocytopenia (HIT);(d) The STAR Trial to determine the benefit of rituximab added to the usual treatment for TTP;and (e) The trial to assess whether antifibrinolytic treatment reduces bleeding in chronically thrombocytopenic patients. Only through multi-center clinical trials can answers to these problems be addressed. Successful completion of these studies will have a major impact upon the public health in several ways. These studies will significantly alter clinical practice regarding the dose of platelets and FFP to be administered and should result in a major reduction in the costs of transfusion nationwide. They will also establish for the first time the appropriate treatment for uncommon diseases such as HIT, TTP, and chronic thrombocytopenia.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL072299-08
Application #
8138390
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Mondoro, Traci
Project Start
2002-09-30
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2012
Total Cost
$82,688
Indirect Cost
$26,813
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Triulzi, Darrell J; Assmann, Susan F; Strauss, Ronald G et al. (2012) The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 119:5553-62
Josephson, Cassandra D; Granger, Suzanne; Assmann, Susan F et al. (2012) Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 120:748-60
Kuter, David J (2010) Biology and chemistry of thrombopoietic agents. Semin Hematol 47:243-8
Slichter, Sherrill J; Kaufman, Richard M; Assmann, Susan F et al. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362:600-13
Steiner, M E; Assmann, S F; Levy, J H et al. (2010) Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7). Transfus Apher Sci 43:107-16
Kuter, David J (2009) New thrombopoietic growth factors. Clin Lymphoma Myeloma 9 Suppl 3:S347-56
Kuter, David J; Gernsheimer, Terry B (2009) Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am 23:1193-211
Kuter, David J (2009) Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 60:193-206
Kuter, David J; Bain, Barbara; Mufti, Ghulam et al. (2007) Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 139:351-62
Kuter, David J (2007) New thrombopoietic growth factors. Blood 109:4607-16

Showing the most recent 10 out of 13 publications